609 related articles for article (PubMed ID: 16488571)
21. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
[TBL] [Abstract][Full Text] [Related]
22. Antiosteoporotic activity of Saururus chinensis extract in ovariectomized rats.
Sung MJ; Davaatseren M; Hur HJ; Kim HJ; Ryu SY; Choi YH; Cha MR; Kwon DY
Phytother Res; 2012 Aug; 26(8):1182-8. PubMed ID: 22821855
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the relationship between dynamic pattern of nighttime levels of melatonin and chosen biochemical markers of bone metabolism in a rat model of postmenopausal osteoporosis.
Ostrowska Z; Kos-Kudla B; Swietochowska E; Marek B; Kajdaniuk D; Górski J
Neuro Endocrinol Lett; 2001 Apr; 22(2):129-36. PubMed ID: 11335889
[TBL] [Abstract][Full Text] [Related]
24. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
25. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
26. Low-level lifetime exposure to cadmium decreases skeletal mineralization and enhances bone loss in aged rats.
Brzóska MM; Moniuszko-Jakoniuk J
Bone; 2004 Nov; 35(5):1180-91. PubMed ID: 15542044
[TBL] [Abstract][Full Text] [Related]
27. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
28. Effects of cod bone gelatin on bone metabolism and bone microarchitecture in ovariectomized rats.
Han X; Xu Y; Wang J; Pei X; Yang R; Li N; Li Y
Bone; 2009 May; 44(5):942-7. PubMed ID: 19124090
[TBL] [Abstract][Full Text] [Related]
29. Circadian rhythm affects the preventive role of pulsed electromagnetic fields on ovariectomy-induced osteoporosis in rats.
Jing D; Shen G; Huang J; Xie K; Cai J; Xu Q; Wu X; Luo E
Bone; 2010 Feb; 46(2):487-95. PubMed ID: 19782781
[TBL] [Abstract][Full Text] [Related]
30. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Ravn P; Clemmesen B; Christiansen C
Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
[TBL] [Abstract][Full Text] [Related]
31. Effect of oral contraceptive treatment on bone mass acquisition in skeletally immature young female rats.
Eleftheriades MI; Lambrinoudaki IV; Christodoulakos GE; Gregoriou OV; Economou EV; Kouskouni EE; Antoniou AG; Perrea DN; Dontas IA; Raptou PD; Lyritis GP; Creatsas GC
Contraception; 2005 May; 71(5):362-71. PubMed ID: 15854638
[TBL] [Abstract][Full Text] [Related]
32. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
[TBL] [Abstract][Full Text] [Related]
33. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
34. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
[TBL] [Abstract][Full Text] [Related]
35. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
Di Somma C; Colao A; Pivonello R; Klain M; Faggiano A; Tripodi FS; Merola B; Salvatore M; Lombardi G
Clin Endocrinol (Oxf); 1998 May; 48(5):655-62. PubMed ID: 9666879
[TBL] [Abstract][Full Text] [Related]
37. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys.
Stroup GB; Kumar S; Jerome CP
Calcif Tissue Int; 2009 Oct; 85(4):344-55. PubMed ID: 19763376
[TBL] [Abstract][Full Text] [Related]
38. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
[TBL] [Abstract][Full Text] [Related]
39. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological treatment of osteopenia induced by gastrectomy or ovariectomy in young female rats.
Andersson N; Surve VV; Lehto-Axtelius D; Andersson K; Ryberg B; Ohlsson C; Håkanson R
Acta Orthop Scand; 2004 Apr; 75(2):201-9. PubMed ID: 15180236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
